The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
Newsable Asianet News on MSN1d
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...
The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and head and neck, per the results published in the journal Cancer.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback